Incyte Corporation

Bwt Property, Inc.

Other

Incyte Holdings Corporation

Lexicon Pharmaceuticals, Inc.

Prelude Therapeutics Incorporated

B&w Tek LLC

B & W Property Inc.

B&w Tek Property, Inc.

Qun Li

Zhongjiang Jia

Sean Xiaolu Wang

Jiacheng Zhou

Yongchun Pan

Yongzhong Wu

Ganfeng Cao

Lei Qiao

Pingli Liu

Shili Chen

Yun-Long Li

Jincong Zhuo

Ding-Quan Qian

Song Mei

Hui-Yin Li

Michael Xia

Wayne Han

Chongsheng Eric Shi

Timothy Martin

Chu-Biao Xue

Matthew Mangzhu Zhao

Qiyan Lin

Vaqar Sharief

Rongsheng Tian

Wenqing Yao

James David Rodgers

Bo Shen

Stacey Shepard

Anlai Wang

Taisheng Huang

Changsheng Zheng

Xin Jack Zhou

Qingxiong Li

Lixin Shao

Haiming Zhang

Wenxue Wu

Haisheng Wang

David J Meloni

Ming Tao

Hai Fen Ye

Timothy C Burn

Xiaogen Yang

William Frietze

Susan Margaret De Paul

Naijing Su

Weifeng Hu

Dengjin Wang

Sheng Yao

Yang Ye

Yi Li

Phillip C Liu

Bayou Mi

Jiangqiong Zhao

Huaping Zhang

Hongwu Yu

Ling Kong

The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Crystalline solid forms of a BET inhibitor

The disclosure is directed to pharmaceutically acceptable salts of the compound of Formula I (I). Pharmaceutical compositions comprising pharmaceutically acceptable salts of the compound of Formula I, as well as methods of their use and preparation, are also described.

Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Salts of the AAK1 inhibitor (S)-1-((2',6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and solid forms thereof are disclosed, as are pharmaceutical formulations comprising them and methods of their preparation.

Solid forms of (S)-1-((2',6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof

The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Bipyrazole derivatives as JAK inhibitors

This invention provides a UV spectroscopy apparatus and method for controlled drug waste diversion detection. The spectroscopy apparatus employs sample cells which have optimized optical path length such that the measured maximum absorbance of the drug is less than the detection limit of the system. Hence the full unsaturated absorption spectrum of the drug is revealed in the UV wavelength region from 230 nm (or even down to 195 nm) to 400 nm. This full spectrum analysis improves the specificity for drug identification and the accuracy for drug concentration verification. The spectral library of the apparatus comprises the spectra of common controlled drugs, excipients, as well as typical diluents, which enables the identification of controlled drugs from different manufacturers and/or diluted with different types of diluents.

Apparatus and methods for controlled drug waste diversion detection

The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.

Salts of TAM inhibitors

The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.

Salts of a Pim kinase inhibitor

Crystalline solid forms of a bet inhibitor

The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2′:5,6]pyrido[4,3-d]pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.

Salts of an FGFR inhibitor

This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.

Salts and crystalline forms of a PD-1/PD-L1 inhibitor

This invention provides a UV spectroscopy apparatus and method for controlled drug waste diversion detection. The spectroscopy apparatus employs sample cells which have optimized optical path length such that the measured maximum absorbance of the drug is less than the detection limit of the system. Hence the full unsaturated absorption spectrum of the drug is revealed in the UV wavelength region from 230 nm (or even down to 195 nm) to 400 nm. This full spectrum analysis improves the specificity for drug identification and the accuracy for drug concentration verification. The spectral library of the apparatus comprises the spectra of preservative-free controlled drugs, common excipients, as well as typical diluents, which enables the identification of controlled drugs from different manufacturers and/or diluted with different types of diluents.

The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2&#x2032;-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.

Salts of a PD-1/PD-L1 inhibitor

The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase. Particular embodiments contemplate compounds and disease indications amenable to treatment by modulation of lysine specific demethylase-1 (LSD1).

Salts of an LSD1 inhibitor and processes for preparing the same

Growing community of inventors

Newark, DE, United States of America

Qun Li